MaaT Pharma, a frontrunner in the field of microbiome-driven immunomodulation for oncology, is thrilled to announce a successful funding round totaling €37,500,000. This milestone represents not only a significant vote of confidence from investors but also reinforces the company’s commitment to leveraging its proprietary pooling and co-cultivation technologies to transform cancer treatment. Based in Lyon, France, and founded in 2014, MaaT Pharma has rapidly become a beacon of innovation, pioneering the development of the first microbiome-driven immunomodulator aimed at enhancing survival for cancer patients globally. The newly secured funds will be strategically invested in advancing late-stage clinical programs and further refining its cutting-edge therapies that work by modulating the immune system through high diversity, standardized drug candidates derived from the gut microbiome.
This infusion of capital is expected to accelerate clinical trials, deepen research collaborations, and expand the company’s technological capabilities, ensuring that promising treatments move swiftly from the lab to the clinic. Moreover, the funds will support the development of robust manufacturing processes that meet the stringent standards necessary for regulatory approval, reinforcing MaaT Pharma’s position in the global market. Listed on Euronext Paris since 2021 under the ticker MAAT, the company continues to build on its solid foundation of science and clinical innovation. MaaT Pharma’s dedication to extending life and improving the quality of life for cancer patients worldwide stands as a testament to the innovative spirit and unwavering commitment that drive every facet of its operations. This funding round marks an exciting new chapter in MaaT Pharma’s journey toward revolutionizing oncology care through groundbreaking microbiome research.
